- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 231/18 - One oxygen or sulfur atom
Patent holdings for IPC class C07D 231/18
Total number of patents in this class: 315
10-year publication summary
|
22
|
27
|
18
|
45
|
31
|
23
|
12
|
12
|
13
|
11
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Inflazome Limited | 85 |
24 |
| Theravance Biopharma R&D IP, LLC | 460 |
14 |
| Bristol-myers Squibb Company | 4872 |
8 |
| The University of Queensland | 659 |
8 |
| Novartis AG | 10882 |
7 |
| Arena Pharmaceuticals, Inc. | 366 |
7 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 163 |
7 |
| BASF SE | 20874 |
6 |
| Northwestern University | 3369 |
6 |
| Cardioxyl Pharmaceuticals, Inc. | 49 |
6 |
| VALO Health, Inc. | 172 |
6 |
| Bayer Pharma AG | 1061 |
5 |
| The Johns Hopkins University | 5651 |
5 |
| Nippon Soda Co., Ltd. | 893 |
5 |
| Abbott Laboratories | 2411 |
4 |
| Bayer AG | 3319 |
4 |
| Takeda Pharmaceutical Company Limited | 2707 |
4 |
| Merial, Inc. | 220 |
4 |
| Nissan Chemical Corporation | 1989 |
4 |
| Sumitomo Pharma Co., Ltd. | 609 |
4 |
| Other owners | 177 |